Huangpu innovative pharmaceutical company leads domestic market

Akeso has announced that its PD-1/VEGF dual antibody, Ivonescimab, which is under clinical research, has shown significant advantages over "Keytruda", becoming the world's first drug to demonstrate such effectiveness.

Keytruda is the world's best-selling PD-1 monoclonal antibody, with sales reaching $25 billion in 2023. In a head-to-head trial, Yivoci emerged victorious, attracting global attention.

Production building of Akeso. [Photo/WeChat account: gzhpfb]

Akeso has been quietly developing the antibody for twelve years, demonstrating its strong scientific research capabilities. Ivonescimab and Cadonilimab are manufactured in Guangzhou and are ready to expand abroad. Akeso focuses on the field of dual antibodies, which can target two points simultaneously, providing stronger efficacy and better safety than regular antibodies.

Akeso has made a significant breakthrough in the field of cancer immunotherapy, changing the treatment landscape. Akeso is the only global biopharmaceutical company with two novel cancer immunotherapy dual antibodies. The Guangzhou Development District has provided crucial support, offering various types of assistance to make Akeso more competitive globally.

Akeso's development showcases the vitality and potential of the Chinese biopharmaceutical industry, bringing new hope to patients at home and abroad.

Share - WeChat